Patient Satisfaction after Switching to Paroxetine CR: A Follow-up Study Using HSDS/HSAS (Himorogi Self-rating Depression/Anxiety Scale)

Patient Satisfaction after Switching to Paroxetine CR: A Follow-up Study Using HSDS/HSAS (Himorogi Self-rating Depression/Anxiety Scale) - Patient Satisfaction after Switching to Paroxetine CR

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010950

Enrollment

120

Registered

2013-06-13

Start date

2012-06-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

A total of 256 patients were enrolled in the study: 205 patients who switched from paroxetine IR to paroxetine CR and 51 naive patients. Out of them, 139 switchover patients and 29 naive patients, who

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The inclusion criteria were as follows: 1) Those aged 18 or over with MDD or anxiety disorder complication of MDD (by DSM-IV-TR). 2) Those treated with stable doses of paroxetine IR for at least 24 weeks presenting with stable symptoms, or those newly treated with paroxetine CR. 3) Gender and frequencies of past depression episodes do not matter.

Exclusion criteria

Exclusion criteria: The exclusion criteria were as follows: 1) Those with convulsive disorders such as schizophrenia and epilepsia or their previous history. 2) Those with depression or depressive state caused by organic brain damages. 3) Those with severe disorders in liver, kidney, blood or circulation. 4) Those with malignancy or its previous history. 5) Those pregnant, nursing, or who may become pregnant. 6) Those with heavy suicidal tendency, previous history of suicidal ideation, or suicide attempt. 7) Those with personality disorder, mental retardation or intractable depression at a physician's discretion. 8) Those with substance dependence or drug abuse (excluding disorders related to nicotine). 9) Those who have had modified doses of concomitant drugs (excluding paroxetine CR) during the last 8 weeks.

Design outcomes

Primary

Measure	Time frame
The primary endpoints of efficacy are the frequencies of adverse drug reactions (ADRs) as well as the total scores of HSDS/HSAS (Himorogi Self-rating Depression/Anxiety Scale) evaluated at the time of medication change from paroxetine IR to paroxetine CR (0W), during the 4th week (4W), and during the 8th week (8W) of the trial.	—

Countries

Japan

Contacts

Public ContactYoshinori Watanabe

Himorogi Psychiatric Institute Head Director

watanabe@himorogi.org03-5940-5547

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026